Literature DB >> 27358676

Predictors of long term survival after hepatic resection for hilar cholangiocarcinoma: A retrospective study of 5-year survivors.

Mohamed Abd ElWahab1, Ayman El Nakeeb1, Ehab El Hanafy1, Ahmad M Sultan1, Ahmed Elghawalby1, Waleed Askr1, Mahmoud Ali1, Mohamed Abd El Gawad1, Tarek Salah1.   

Abstract

AIM: To determine predictors of long term survival after resection of hilar cholangiocarcinoma (HC) by comparing patients surviving > 5 years with those who survived < 5 years.
METHODS: This is a retrospective study of patients with pathologically proven HC who underwent surgical resection at the Gastroenterology Surgical Center, Mansoura University, Egypt between January 2002 and April 2013. All data of the patients were collected from the medical records. Patients were divided into two groups according to their survival: Patients surviving less than 5 years and those who survived > 5 years.
RESULTS: There were 34 (14%) long term survivors (5 year survivors) among the 243 patients. Five-year survivors were younger at diagnosis than those surviving less than 5 years (mean age, 50.47 ± 4.45 vs 54.59 ± 4.98, P = 0.001). Gender, clinical presentation, preoperative drainage, preoperative serum bilirubin, albumin and serum glutamic-pyruvic transaminase were similar between the two groups. The level of CA 19-9 was significantly higher in patients surviving < 5 years (395.71 ± 31.43 vs 254.06 ± 42.19, P = 0.0001). Univariate analysis demonstrated nine variables to be significantly associated with survival > 5 year, including young age (P = 0.001), serum CA19-9 (P = 0.0001), non-cirrhotic liver (P = 0.02), major hepatic resection (P = 0.001), caudate lobe resection (P = 0.006), well differentiated tumour (P = 0.03), lymph node status (0.008), R0 resection margin (P = 0.0001) and early postoperative liver cell failure (P = 0.02).
CONCLUSION: Liver status, resection of caudate lobe, lymph node status, R0 resection and CA19-9 were demonstrated to be independent risk factors for long term survival.

Entities:  

Keywords:  CA19-9; Caudate lobe resection; Hepatic resection; Hilar cholangiocarcinoma; Liver cell failure

Year:  2016        PMID: 27358676      PMCID: PMC4919711          DOI: 10.4240/wjgs.v8.i6.436

Source DB:  PubMed          Journal:  World J Gastrointest Surg


  40 in total

1.  Single centre experience with surgical treatment of hilar cholangiocarcinoma.

Authors:  N Vladov; Ts Lukanova; I Takorov; V Mutafchiyski; I Vasilevski; S Sergeev; E Odisseeva
Journal:  Chirurgia (Bucur)       Date:  2013 May-Jun

Review 2.  Surgical treatment in proximal bile duct cancer. A single-center experience.

Authors:  R Pichlmayr; A Weimann; J Klempnauer; K J Oldhafer; H Maschek; G Tusch; B Ringe
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

3.  Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor).

Authors:  Sander Dinant; Michael F Gerhards; E A J Rauws; Olivier R C Busch; Dirk J Gouma; Thomas M van Gulik
Journal:  Ann Surg Oncol       Date:  2006-04-14       Impact factor: 5.344

4.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

5.  Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation.

Authors:  S Iwatsuki; S Todo; J W Marsh; J R Madariaga; R G Lee; I Dvorchik; J J Fung; T E Starzl
Journal:  J Am Coll Surg       Date:  1998-10       Impact factor: 6.113

6.  Improved survival following right trisectionectomy with caudate lobectomy without operative mortality: surgical treatment for hilar cholangiocarcinoma.

Authors:  Kwang Yeol Paik; Dong Wook Choi; Jun Chul Chung; Kyung Tae Kang; Sang Bum Kim
Journal:  J Gastrointest Surg       Date:  2008-03-11       Impact factor: 3.452

7.  Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.

Authors:  Sung Gyu Lee; Gi Won Song; Shin Hwang; Tae Yong Ha; Deok Bog Moon; Dong Hwan Jung; Ki Hun Kim; Chul Soo Ahn; Myung Hwan Kim; Sung Koo Lee; Kyu Bo Sung; Gi Young Ko
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-10-23       Impact factor: 7.027

8.  Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver.

Authors:  H Bismuth; M B Corlette
Journal:  Surg Gynecol Obstet       Date:  1975-02

Review 9.  Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system.

Authors:  E C Burke; W R Jarnagin; S N Hochwald; P W Pisters; Y Fong; L H Blumgart
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

10.  Surgical treatment of 144 cases of hilar cholangiocarcinoma without liver-related mortality.

Authors:  Norihiko Furusawa; Akira Kobayashi; Takahide Yokoyama; Akira Shimizu; Hiroaki Motoyama; Sin-ichi Miyagawa
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

View more
  3 in total

1.  A long-term survivor of hilar cholangiocarcinoma with resection of recurrent peritoneal dissemination after R0 surgery: a case report.

Authors:  Tatsunori Miyata; Hirohisa Okabe; Akira Chikamoto; Takanobu Yamao; Naoki Umezaki; Masayo Tsukamoto; Yuki Kitano; Kota Arima; Shigeki Nakagawa; Katsunori Imai; Daisuke Hashimoto; Yo-Ichi Yamashita; Hideo Baba
Journal:  Surg Case Rep       Date:  2017-10-16

2.  The value of caudate lobectomy in hilar cholangiocarcinoma treatment: A meta-analysis.

Authors:  Ming Yang; Wei Wei Li; Jian Hua Chen; Miao Hang Cui; Jin Long Liu
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

3.  Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma.

Authors:  Jang Han Jung; Hyun Jik Lee; Hee Seung Lee; Jung Hyun Jo; In Rae Cho; Moon Jae Chung; Jeong Youp Park; Seung Woo Park; Si Young Song; Seungmin Bang
Journal:  World J Gastroenterol       Date:  2017-05-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.